Topic: idiopathic pulmonary fibrosis
The series C sets Galecto up to power into late-phase development despite Bristol-Myers Squibb passing up the chance to buy it out.
Roivant Sciences’ spinout machine keeps turning with the launch of the lung-focused Respivant Sciences, with tech and staff from Patara Pharma.
Pliant Therapeutics has raised a healthy $62 million series B to help fund its proof of concept tests across a range of scarring diseases.
Scientists have amassed evidence that the metformin's ability to target cell metabolism could help repair the lung.
Galecto Biotech hired Richard Marshall, head of fibrosis discovery at GlaxoSmithKline, to be CMO as it moves into late-phase trials of its IPF drug.
The ROCK2 inhibitor had a stronger effect on FVC than standard of care, but the lack of detail in the top-line data leave scope for doubts.
Following poor results from Roche and AstraZeneca, Sanofi says it is canning a phase 2 trial in idiopathic pulmonary fibrosis.
After a failed trial in May, AstraZeneca hoped tralokinumab could pass subpopulation tests and make it to the finish line, but it wasn’t meant to be.
California biotech Global Blood Therapeutics is canning its work in idiopathic pulmonary fibrosis (IPF).
Belgian biotech Galapagos has chalked up a positive phase 2a trial for its idiopathic pulmonary fibrosis (IPF) drug GLPG1690, saying it halted the relentless decline in lung function normally seen in patients.